Open Access

Longitudinal changes in insulin sensitivity, insulin secretion, beta cell function and glucose effectiveness during development of non-diabetic hyperglycemia in a Japanese population

SpringerPlus20143:252

https://doi.org/10.1186/2193-1801-3-252

Received: 27 March 2014

Accepted: 15 May 2014

Published: 20 May 2014

Abstract

Since there had been no previous studies of alterations in insulin sensitivity, glucose-stimulated insulin secretion, beta cell function and glucose effectiveness during the development of non-diabetic hyperglycemia in Asian populations, we conducted a longitudinal study of such changes in 244 Japanese adults with normal glucose tolerance (median BMI 23.3 kg/m2 and age 51 yrs). The median follow-up period was 3.3 yrs. One hundred and eighty-two subjects maintained normal glucose tolerance (nonprogressors). After excluding the 3 subjects who progressed to diabetes, we analyzed the 59 who developed non-diabetic hyperglycemia (progressors), of which 31 progressed to impaired fasting glucose and 28 to impaired glucose tolerance. Whole body insulin sensitivity was estimated by ISIMatsuda, glucose-stimulated insulin secretion by [δIRI0-30/δPG0-30] and Stumvoll indices, hepatic insulin sensitivity by quantitative insulin sensitivity check index (QUICKI) and 1/fasting IRI, beta cell function by oral disposition index (DIO) ([δIRI0-30/δPG0-30]∙[ISIMatsuda]), and glucose effectiveness by an OGTT-derived index (SgIO). ISIMatsuda (p <0.05), [δIRI0-30/δPG0-30], DIO and SgIO (both p <0.01), but not QUICKI, 1/fasting IRI, or Stumvoll-1st and -2nd phases, were lower in the progressors at baseline. This group was also characterized by the following: 1) ISIMatsuda, DIO and SgIO were reduced by 34%, 32% and 11%, respectively (all p <0.01); 2) QUICKI and 1/fasting IRI diminished by 21% and 5%, respectively (both p <0.01); and 3) no significant changes were found in [δIRI0-30/δPG0-30], Stumvoll-1st and -2nd phases or BMI during the follow-up. In the nonprogressors, no indices changed significantly during the follow-up. Our study concluded that during the transition from normal glucose tolerance to non-diabetic hyperglycemia in this non-obese population, whole body insulin sensitivity, hepatic insulin sensitivity, beta cell function, and glucose effectiveness were all attenuated, but no significant changes in glucose-stimulated insulin secretion occurred. Also of note is the fact that the transition took place without any accompanying increase in BMI.

Keywords

Non-diabetic hyperglycemiaInsulin sensitivityInsulin secretionBeta cell functionGlucose effectiveness

Background

In obese subjects with normal glucose tolerance (NGT), a lowering of insulin sensitivity (SI) during the development of non-diabetic hyperglycemia (NDH) has commonly been observed (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999). The picture with regard to glucose-stimulated insulin secretion (GSIS), however, has not been entirely consistent. In one previous study, GSIS increased significantly in the nonprogressors but decreased in the progressors (Weyer et al. 1999), whereas other investigators found that, while the indices of beta cell function decreased, the total insulin output over the 2 h of the oral glucose tolerance test increased in the progressors (Ferrannini et al. 2011). A third study reported no significant increase in GSIS in either the nonprogressors or progressors (Faerch et al. 2009).

In Japan, subjects in the general population are largely non-obese. Diabetes without overt obesity is common (Matsuba et al. 2012), and it is possible that the natural course of the worsening of glucose metabolism in the Japanese is different from that in obese populations (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999). Cross-sectional studies have shown that SI and GSIS were significantly attenuated in Japanese subjects with minute elevations of plasma glucose (PG) within the normal range, and the attenuation was progressively greater with increasing levels of PG across NDH and diabetes mellitus (DM) (Sato et al. 2002; Oka et al. 2012). However, there have been no reports of longitudinal alterations in SI, GSIS or beta cell function (BCF) during the progression from NGT to NDH in Japanese subjects, or in any other non-obese population.

In a previous study, we found that the attenuation of whole body SI and GSIS at baseline in Japanese subjects with NGT was significantly related to a worsening of the glucose metabolism (Oka et al. 2014a). Our next step was to attempt to clarify the longitudinal changes in SI, GSIS and BCF during the progression from NGT to NDH. Because the attenuation of glucose effectiveness (Sg) has been identified as an important element in the worsening of the glucose metabolism (Goldfine et al. 2003; Tonelli et al. 2005), we also examined the longitudinal changes in Sg by using an OGTT-derived index, SgIO (Nagasaka et al. 2012).

Results and discussion

The baseline characteristics for the health examinees with NGT whose immunoreactive insulin (IRI) was determined at the follow-up OGTT were similar to those whose IRI was not measured at the follow-up OGTT, except that the subjects in the former group were slightly younger and had slightly lower 2hIRI values. Importantly, the incidence rate of NDH did not differ significantly between the two groups (Additional file 1: Table S1). It was the examinees whose IRI had been measured upon follow-up (n = 244) who became the subjects of the present study.

At the end of the follow-up, 182 participants remained in the NGT category and were classified as nonprogressors. The rest had progressed to NDH or DM. Those who had progressed to impaired fasting glucose (IFG) (n = 31) and impaired glucose tolerance (IGT) (n = 28) were collectively classified as progressors (n = 59), and the data from both the nonprogressors and progressors were analyzed. The subjects who progressed to DM (n = 3) were excluded from the analysis.

The characteristics of the 241 subjects analyzed in this study are shown in Table 1. Male gender and a family history of diabetes were significantly more frequent in the progressors than in the nonprogressors, and the changes in fasting plasma glucose (FPG) and 2hPG in male subjects were significantly greater compared to those in female subjects (p = 0.04 for FPG and p <0.01 for 2hPG). At baseline, BMI, FPG, 2hPG and 2hIRI were significantly higher in the progressors than in the nonprogressors. On the other hand, ISIMatsuda, insulinogenic index (δIRI0-30/δPG0-30), the product of insulinogenic index and ISIMatsuda (DIOII), the product of Stumvoll-1 and ISIMatsuda (DIOST-1) and SgIO were significantly lower in the progressors than in the nonprogressors at baseline. During the follow-up, none of the indices in the nonprogressors changed significantly. In the progressors, ISIMatsuda, the quantitative insulin sensitivity check index (QUICKI) and 1/fasting IRI (1/FIRI) decreased by 34%, 5% and 21%, respectively (all p <0.01). δIRI0-30/δPG0-30 increased while Stumvoll-1 and -2 decreased but in neither case significantly. The progressors also experienced attenuation of DIOII, DIOST-1 and SgIO by 32% (p <0.05), 32% (p <0.01) and 11% (p <0.01), respectively, during the follow-up, with minimal, insignificant decreases in BMI. Changes in ISIMatsuda and progression to NDH were significantly correlated after adjustment for age, gender, family history of diabetes, baseline BMI, follow-up period and change in BMI in the entire population (β = -0.15, p = 0.02).
Table 1

Characteristics of the participants analyzed in this study

Variables

 

All

   Subgroup

   

Non-progressors

Progressors

n

241

182

59

Age, yr

51(46–57)

50(45–57)

52(47–57)

Men/women

163/78

113/69

50/9§

Family Hx of diabetes, +/-

32/209

19/163

13/46‡

 

Baseline

Follow-up

Baseline

Follow-up

Baseline

Follow-up

BMI, kg/m2

23.3(21.3–25.3)

23.2(21.3–25.4)

22.9(21.0–24.9)

23.0(20.9–25.0)

24.4(22.6–24.4)

24.2(22.8–26.0)

FPG, mg/dL

93(89–96)

94(90–97)†

92(89–95)

92(89–95)

95(91–97)

101(94–105)†

2hPG, mg/dL

104(93–116)

106(92–119)†

102(91–113)

103(90–114)

114(103–123)

134(109–155)†

FIRI, μU/mL

3.4(2.6–4.8)

3.6(2.8–5.1)

3.3(2.6–4.5)

3.4(2.7–4.6)

3.7(2.6–5.3)

4.4(3.6–5.8)†

2hIRI, μU/mL

19.3(12.3–29.6)

21.6(14.0–35.8)†

18.5(10.8–27.2)

19.5(13.4–32.2)

25.1(16.6–35.0)

31.9(19.9–49.5)†

ISIMatsuda

12.8(9.3–18.8)

11.5(7.5–16.4)†

13.2(10.2–19.4)

12.4(9.3–17.3)

11.1(8.3–17.8)

7.3(5.3–11.0)†

QUICKI

0.400(0.378–0.421)

0.396(0.376–0.417)*

0.400(0.380–0.424)

0.401(0.381–0.422)

0.393(0.372–0.420)

0.377(0.363–0.391)†

1/FIRI

0.29(0.21–0.38)

0.28(0.20–0.36)

0.30(0.22–0.39)

0.29(0.22–0.37)

0.28(0.19–0.40)

0.23(0.17–0.28)†

Insulinogenic index

0.61(0.36–1.10)

0.63(0.40–1.03)

0.65(0.39–1.12)

0.69(0.45–1.12)

0.48(0.29–0.90)

0.52(0.29–0.91)

Stumvoll-1

740.1(529.4–952.5)

753.2(571.3–1033.0)

755.5(561.7–967.4)

776.8(619.5–1030.3)

694.8(504.2–864.5)

638.2(448.7–869.8)

Stumvoll-2

205.2(161.6–251.8)

209.5(174.1–263.2)

206.8(168.4–252.8)

211.0(182.2–267.8)

199.0(155.3–236.5)

188.8(146.0–237.1)

DIO

7.78(4.38–15.52)

6.89(3.48–12.06)

8.73(5.27–17.2)

8.25(5.18–15.23)

5.16(3.28–9.33)

3.24(2.09–5.72)†

SgIo

3.27(2.87–3.88)

3.28(2.73–3.76)

3.41(2.93–3.97)

3.43(2.94–3.93)

3.04(2.65–3.65)

2.70(2.19–3.36)†

Ratio

  ISIMatsuda

0.84(0.61–1.73)

0.96(0.64–1.31)

0.66(0.45–0.86)§

  QUICKI

1.00(0.94–1.10)

1.00(0.96–1.05)

0.95(0.90–1.01)§

  1/FIRI

0.97(0.71–1.79)

1.00(0.79–1.31)

0.79(0.58–1.06)§

  Insulinogenic index

0.99(0.66–1.59)

0.99(0.68–1.58)

1.01(0.63–1.86)

  Stumvoll-1

1.02(0.78–1.65)

1.03(0.80–1.31)

0.98(0.68–1.44)

  Stumvoll-2

1.03(0.83–1.50)

1.03(0.84–1.23)

1.02(0.78–1.31)

  DIO

0.88(0.45–1.61)

0.93(0.47–1.70)

0.68(0.37–1.27)‡

  SgIo

0.99(0.91–1.05)

1.01(0.95–1.06)

0.89(0.78–0.96)§

Follow-up period, yr

3.3(2.2–4.1)

3.4(2.1–4.1)

3.1(2.2–4.7)

Numerical data is the median (25–75 percentile). Progressors comprise those who progressed to impaired fasting glucose and impaired glucose tolerance. BMI, body mass index; FPG, fasting plasma glucose; 2hPG, PG 2-h after oral intake of 75 g glucose; FIRI, fasting immunoreactive insulin; 2hIRI, IRI after oral intake of 75 g glucose; ISIMatsuda, Matsuda insulin sensitivity index; QUICKI, quantitative insulin sensitivity check index; Insulinogenic index, δIRI0-30/δPG0-30; Stumvoll-1, Stumvoll index of first phase insulin secretion; Stumvoll-2, Stumvoll index of second phase insulin secretion; DIO, oral disposition index (product of Insulinogenic index and ISIMatsuda); SgIO, index of glucose effectiveness derived from OGTT. Ratio denotes [follow-up value/baseline value] of each variable in each subject. *and †, p <0.05 and <0.01, respectively, compared to the corresponding baseline values by Wilcoxon’s signed rank test; ‡ and §, p <0.05 and <0.01, respectively, compared to the corresponding values in nonprogressors by Fisher’s exact test or Wilcoxon’s signed rank test. See Text for detail.

When, at the end of the follow-up, a group-wise comparison was made between the nonprogressors and the progressors, the absolute values for BMI, FIRI, and 2hIRI were significantly higher, and ISIMatsuda, 1/FIRI, QUICKI, δIRI0-30/δPG0-30, Stumvoll-1 and -2, DIOII, DIOST-1, and SgIO significantly lower in the latter group (p <0.05 for Stumvoll-2 and <0.01 for other variables). Because baseline values differed significantly for some variables between the nonprogressors and the progressors, the degrees of change, i.e. the ratios, in the nonprogressors and the progressors were also compared by Mann-Whitney U test. FIRI and 2hIRI increased more significantly in the progressors than in the nonprogressors and ISIMatsuda, 1/FIRI, QUICKI, DIOII, DIOST-1 and SgIO were more significantly attenuated in the nonprogressors than in the progressors.

In this study, we aimed to clarify the longitudinal changes during the development of NDH in Japanese subjects, a non-obese population. The seminal findings were as follows. In the progressors, ISIMatsuda, QUICKI, 1/FIRI, DIOII, DIOST-1 and SgIO were attenuated during the follow-up, which was associated with insignificant changes in δIRI0-30/δPG0-30, Stumvoll-1 and Stumvol-2. In the nonprogressors, none of the variables showed significant changes during the follow-up. Overall, our data showed that an attenuation of hepatic and whole body SI, BCF and Sg, on top of already lowered whole body SI, early phase GSIS, BCF and Sg, took place during the transition from NGT to NDH in this population. Among the changes occurring during the development of NDH, the lowering of whole body SI and BCF was the most prominent, and the lowering of whole body SI and progression to NDH were independently correlated. Also of note is the fact that in the progressors, these changes occurred in the absence of weight gain.

There are both similarities and dissimilarities between our data and the data obtained in previous longitudinal studies which analyzed the natural course of the development of NDH in obese, WHO-defined NGT subjects (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999). A lowering of SI in the progressors during the development of NDH is a common finding in all studies (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999; current study). On the other hand, the GSIS data differ significantly (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999; current study). In a study of Pima Indians (Weyer et al. 1999), GSIS increased significantly with attenuation of SI in the nonprogressors but decreased in the progressors. In Europids, the indices of beta cell function, such as glucose sensitivity, decreased while total insulin output over the 2 h of the OGTT increased slightly in the progressors (Ferrannini et al. 2011). In another study (Faerch et al. 2009), GSIS did not increase significantly in either in the nonprogressors or the progressors. The study subjects were markedly (Weyer et al. 1999) or slightly (Faerch et al. 2009; Ferrannini et al. 2011) obese, and the participants had further gained weight during the follow-up in all studies (Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al. 1999) except ours (current study). The ‘hyperinsulinemia’ reported in one study (Weyer et al. 1999) may partly have been a reflection of ‘hyperproinsulinemia’ caused by cross-reaction of IRI with proinsulin (Larsson and Ahrén 1999). As far as we are aware, there has been no longitudinal study in which Sg was evaluated during the development of NDH. The present study employed a recently reported index of Sg derived from OGTT (Nagasaka et al. 2012), and is the first documentation of a significant attenuation of Sg with progression from NGT to NDH.

In summary, the major differences between the obese subjects of previous studies and the non-obese subjects in our study were as follows. In the former, there were increases in GSIS in the nonprogressors (Weyer et al. 1999) and decreases in the progressors (Weyer et al. 1999). The indices of beta cell function decreased but total insulin output over the 2 h of the OGTT increased in the progressors (Ferrannini et al. 2011). Furthermore, there was further weight gain in both the nonprogressors and progressors in the obese subjects. In contrast, there were no changes either in GSIS or body weight not only in the nonprogressors but also in the progressors in the non-obese population of our study.

A significant lowering of whole body SI occurred in the progressors without weight gain. This suggested that some factor other than weight gain must have been responsible for the lowering of SI in the progressors. Hepatic steatosis (Oka et al. 2014b; Burgert et al. 2006), sarcopenia (Booth et al. 2012; Narici and Maffulli 2010) and glucose toxicity (Solomon et al. 2012; Del Prato et al. 1994) are all possible underlying mechanisms. The reasons for male preponderance among the progressors are unclear. However, this is compatible with the fact that NDH is more prevalent in men than in women in the general population (Matsuba et al. 2012; Cowie et al. 2009).

The study had its limitations. The sample size was small and the OGTT data consisted of indices of measurements. The follow-up period was not very long so that the eventual disposition of the participants was unknown. The number of subjects who developed NDH was not very large and therefore a subanalysis after separation of the progressors into IFG- and IGT-progressors was not feasible. It is possible that the indices of insulin secretion and insulin sensitivity may be different between IFG and IGT even in non-obese populations and the circumstances of the present study precluded the performance of a sub-group analysis. The indices of SI, GSIS, BCF and Sg were all functions of FPG and 2hPG by definition except for 1/FIRI. In particular, determining BCF by applying DI from OGTT is potentially problematic on account of autocorrelation since both 1st-phase insulin secretion and ISIMatsuda employed the same parameters of fasting glucose and fasting insulin. Therefore, a degree of caution is called for when interpreting the relationship between alterations in the indices and changes in PG. Due to the study design, an unintentional selection bias cannot be entirely ruled out.

Conclusions

Diminution of whole body and hepatic SI, BCF and Sg occurred during transition from NGT to NDH without significant changes in GSIS or body weight in this population. The unchanged GSIS might be an adaptation failure for decreased SI. This may be a common feature of non-obese populations in the early stage of worsening of the glucose metabolism.

Methods

Study sample

A retrospective observational study was conducted using a dataset provided by the Health Service Department of Hokuriku Central Hospital, where public school employees receive annual medical checkups. Out of an initial 604 consecutive subjects with NGT who received a subsequent 75 g OGTT (Oka et al. 2014a; Yamauchi et al. 2013), 244 whose IRI was measured both at the basal and subsequent OGTT before March 2012 (the median follow-up period being 3.3 yrs), were selected for further investigation. All of them were Japanese. Signed informed consent was obtained from all subjects, and the Hokuriku Central Hospital Review Board approved the study protocol.

We recommended measurement of IRI to the examinees receiving OGTT, and 244 took up this option, which was offered at an additional cost of approximately 10 euros. It is possible, therefore, that there was an unintentional socio-economic selection bias, i.e., that relatively wealthy people were preferentially recruited. Nevertheless, if there were any baseline phenotypic differences between those who accepted and those who declined our proposal regarding IRI measurement, these differences were neglible (see below).

Measurement of plasma glucose and insulin, and diagnosis of glucose tolerance

PG was analyzed by the glucose oxidase method and IRI by the chemiluminescence method (ADVIA Centaur, Siemens Medical Solutions). The IRI assay does not cross-react with proinsulin (Marcovina et al. 2007). IRI values lower than the detection limit of the assay, 0.4 μU/mL (n = 8), were assumed to be a half of the assay limit, i.e., 0.2 μU/mL. The diagnosis of glucose tolerance category was made according to the 2003 ADA criteria (The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2003).

Calculations

ISIMatsuda was calculated as an index of whole body SI using the fasting and 2 h blood samples: ISIMatsuda = 10,000/[sqrt(FPG∙2hPG∙FIRI∙2hIRI)] (DeFronzo and Matsuda 2010) where FPG and 2hPG denote fasting PG and PG 2 h after 75 g oral glucose load, and FIRI and 2hIRI denote fasting and 2-h post load IRI, respectively. The quantitative insulin sensitivity check index (QUICKI) (Katz et al. 2000) and 1/FIRI (Hermans et al. 1999) were calculated as indices of primarily hepatic SI (Soonthornpun et al. 2003): QUICKI = 1/[log(FPG) + log(FIRI)]. For ISIMatsuda, QUICKI and 1/FIRI, the unit of PG and IRI was mg/dL and μU/mL, respectively (DeFronzo and Matsuda 2010; Katz et al. 2000; Hermans et al. 1999). It should be noted that 1/FIRI is not a function of PG values so that it is free from any autocorrelation with FPG and 2hPG. As an index of early phase GSIS, insulinogenic index (δIRI0-30/δPG0-30) during 75 g OGTT, was employed (Kosaka et al. 1974). As alternative indices of GSIS, Stumvoll 1st (Stumvoll-1) and 2nd phase (Stumvoll-2) indices, respectively, were also used: Stumvoll-1 = 1283 + 1.829∙IRI30 – 138.7∙PG30 + 3.772∙FIRI and Stumvoll-2 = 287 + 0.4164∙IRI30 – 26.07∙PG30 + 0.9226∙FIRI, in which the unit of IRI and PG was pmol/L and mmol/L, respectively (Stumvoll et al. 2000). BCF was estimated by oral disposition indices (DIO): a product of insulinogenic index and ISIMatsuda (DIoII) (Nagasaka et al. 2012; Aizawa et al. 2012) and a product of Stumvoll-1 and ISIMatsuda (DIoST-1) (Oka et al. 2014a; Yamauchi et al. 2013) were employed. As an index of Sg, SgIO which is derived from OGTT (Nagasaka et al. 2012) was calculated. The degree of change for each variable was quantified by calculating [follow-up data/baseline data] ratio. Minus values for Stumvoll-1 and -2 were obtained in 4 and 1 subjects, respectively, and δIRI0-30/δPG0-30 could not be calculated in 13 subjects because the numerator or denominator was zero or minus, and the values for these subjects were assumed to be absent.

Statistics

SPSS version 21.0 was used for statistical analysis. Due to non-normal distribution of the data, all numerical data were expressed as median (25th - 75th percentile). Mann-Whitney U test, Wilcoxon’s signed-rank test, Chi square test and partial correlation were used as needed, and p <0.05 was considered significant.

Abbreviations

ADA: 

American Diabetes Association

BCF: 

Beta cell function

DIO: 

Oral disposition index

DIoII: 

A product of insulinogenic index and ISIMatsuda

DIoST-1: 

A product of Stumvoll 1st phase index and ISIMatsuda

DM: 

Diabetes mellitus

FIRI: 

Fasting immunoreactive insulin

FPG: 

Fasting plasma glucose

GSIS: 

Glucose stimulated insulin secretion

SG: 

Glucose effectiveness

IFG: 

Impaired fasting glucose

IGT: 

Impaired glucose tolerance

IRI: 

Immunoreactive insulin

SgIO: 

Index of glucose effectiveness derived from OGTT

NGT: 

Normal glucose tolerance

PG: 

Plasma glucose

SI: 

Insulin sensitivity

Stumvoll-1: 

Stumvoll 1st phase index

Stumvoll-2: 

Stumvoll 2nd phase index

2hPG: 

PG at 120 min with 75 g OGTT

2hIRI: 

IRI at 120 min with 75 g OGTT

QUICKI: 

Quantitative insulin sensitivity check index.

Declarations

Acknowledgments

The authors thank Dr Rie Oka for giving us an opportunity to analyze the data from the health examinees and for comments which proved invaluable when interpreting the results.

Authors’ Affiliations

(1)
Diabetes Center, Aizawa Hospital
(2)
Clinical Research Department, Kissei Pharmaceutical

References

  1. Aizawa T, Yamada M, Katakura M, Funase Y, Yamashita K, Yamauchi K: Hyperbolic correlation between insulin sensitivity and insulin secretion fades away in lean subjects with superb glucose regulation. Endocr J 2012, 59: 127-136. 10.1507/endocrj.EJ11-0162View ArticleGoogle Scholar
  2. Booth FW, Roberts CK, Laye MJ: Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012, 2: 1143-1211.Google Scholar
  3. Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, Constable RT, Weiss R, Tamborlane WV, Savoye M, Seyal AA, Caprio S: Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006, 91: 4287-4294. 10.1210/jc.2006-1010View ArticleGoogle Scholar
  4. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS: Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care 2009, 32: 287-294.View ArticleGoogle Scholar
  5. DeFronzo RA, Matsuda M: Reduced time points to calculate the composite index. Diabetes Care 2010, 33: e93. 10.2337/dc10-0646View ArticleGoogle Scholar
  6. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA: Effect of sustained physiologic hyperinsulinemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994, 37: 1025-1035. 10.1007/BF00400466View ArticleGoogle Scholar
  7. Faerch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K: Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 2009, 32: 439-444. 10.2337/dc08-1195View ArticleGoogle Scholar
  8. Ferrannini E, Natali A, Muscelli E, Nilsson PM, Golay A, Laakso M, Beck-Nielsen H, Mari A, RISC Investigators: Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 2011, 54: 1507-1516. 10.1007/s00125-011-2112-xView ArticleGoogle Scholar
  9. Goldfine AB, Bouche C, Parker RA, Kim C, Kerivan A, Soeldner JS, Martin BC, Warram JH, Kahn CR: Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. Proc Natl Acad Sci U S A 2003, 100: 2724-2729. 10.1073/pnas.0438009100View ArticleGoogle Scholar
  10. Hermans MP, Levy JC, Morris RJ, Turner RC: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999, 42: 678-687. 10.1007/s001250051215View ArticleGoogle Scholar
  11. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85: 2402-2410. 10.1210/jcem.85.7.6661View ArticleGoogle Scholar
  12. Kosaka K, Hagura R, Kuzuya T, Kuzuya N: Insulin secretory response of diabetics during the period of improvement of glucose tolerance to normal range. Diabetologia 1974, 10: 775-782. 10.1007/BF01219540View ArticleGoogle Scholar
  13. Larsson H, Ahrén B: Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab 1999, 84: 2068-2074.Google Scholar
  14. Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, Campbell SE, Steffes MW, Insulin Standardization Workgroup: Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clin Chem 2007, 53: 711-716. 10.1373/clinchem.2006.082214View ArticleGoogle Scholar
  15. Matsuba I, Saito K, Takai M, Hirao K, Sone H, on behalf of the Japan Diabetes Clinical Data Management Study Group: Fasting insulin levels and metabolic risk factors in type 2 diabetic patients at the first visit in Japan: a 10-year, nationwide, observational study (JDDM 28). Diabetes Care 2012, 35: 1853-1857. 10.2337/dc12-0156View ArticleGoogle Scholar
  16. Nagasaka S, Kusaka I, Yamashita K, Funase Y, Yamauchi K, Katakura M, Ishibashi S, Aizawa T: Index of glucose effectiveness derived from oral glucose tolerance test. Acta Diabetol 2012, 49(Suppl 1):S195-S204.View ArticleGoogle Scholar
  17. Narici MV, Maffulli N: Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010, 95: 139-159. 10.1093/bmb/ldq008View ArticleGoogle Scholar
  18. Oka R, Yagi K, Sakurai M, Nakamura K, Moriuchi T, Miyamoto S, Nohara A, Kawashiri MA, Takeda Y, Yamagishi M: Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr J 2012, 59: 55-64. 10.1507/endocrj.EJ11-0157View ArticleGoogle Scholar
  19. Oka R, Aizawa T, Yagi K, Hayashi K, Kawashiri M, Yamagishi M: Elevated liver enzymes are related to progression to impaired glucose tolerance in Japanese men. Diabet Med 2014, 31: 552-558. 10.1111/dme.12345View ArticleGoogle Scholar
  20. Oka R, Yagi K, Hayashi K, M-a K, Yamagishi M, Yamada M, Fumisawa Y, Yamauchi K, Aizawa T: The evolution of non-diabetic hyperglycemia: a longitudinal study. Endocr J 2014, 61: 91-99. 10.1507/endocrj.EJ13-0359View ArticleGoogle Scholar
  21. Sato Y, Komatsu M, Katakura M, Ohfusa H, Yamada S, Yamauchi K, Hiramatsu K, Ichikawa K, Aizawa T, Hashizume K: Diminution of early insulin response to glucose in subjects with normal but minimally elevated fasting plasma glucose. Evidence for early beta-cell dysfunction. Diabet Med 2002, 19: 566-571. 10.1046/j.1464-5491.2002.00746.xView ArticleGoogle Scholar
  22. Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK: Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab 2012, 97: 4682-4691. 10.1210/jc.2012-2097View ArticleGoogle Scholar
  23. Soonthornpun S, Setasuban W, Thamprasit A, Chayanunnukul W, Rattarasarn C, Geater A: Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab 2003, 88: 1019-1023. 10.1210/jc.2002-021127View ArticleGoogle Scholar
  24. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000, 23: 295-301. 10.2337/diacare.23.3.295View ArticleGoogle Scholar
  25. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160-3167.View ArticleGoogle Scholar
  26. Tonelli J, Kishore P, Lee DE, Hawkins M: The regulation of glucose effectiveness: how glucose modulates its own production. Curr Opin Clin Nutr Metab Care 2005, 8: 450-456. 10.1097/01.mco.0000172588.47811.63View ArticleGoogle Scholar
  27. Weyer C, Bogardus C, Mott D, Pratley R: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104: 787-794. 10.1172/JCI7231View ArticleGoogle Scholar
  28. Yamauchi K, Oka R, Yagi K, Hayashi K, Kawashiri MA, Yamagishi M, Shimbo T, Aizawa T: Population impact of increased body mass index and attenuated beta-cell function on worsening of glucose metabolism in subjects with normal glucose tolerance: a pilot study. Acta Diabetol 2013. Epub ahead of printGoogle Scholar

Copyright

© Aizawa et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.